对癸基苯乙酮 | 37593-06-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 对癸基苯乙酮
• 中文别名: 1-(4-癸基苯基)-1-乙酮
• 英文名称: n-decyl-4' acetophenone
• 英文别名: 4-n-Decylacetophenone；p-n-decylacetophenone；1-(4-decyl-phenyl)-ethanone；1-(4-Decyl-phenyl)-aethanon；p-(n-Decyl)-acetophenon；1-(4-Decylphenyl)ethanone
• CAS: 37593-06-9
• 化学式: C₁₈H₂₈O
• mdl: MFCD00173754
• 分子量: 260.42
• InChiKey: ICORQKDHLXIGHQ-UHFFFAOYSA-N

物化性质

• 熔点：
  33 °C

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  19
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.611
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2914399090

SDS

Name:	1-(4-Decylphenyl)ethan-1-one 97% Material Safety Data Sheet
Synonym:	4-n-Decylacetophenon
CAS:	37593-06-9

Section 1 - Chemical Product MSDS Name:1-(4-Decylphenyl)ethan-1-one 97% Material Safety Data Sheet
Synonym:4-n-Decylacetophenon

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
37593-06-9	1-(4-Decylphenyl)ethan-1-one	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 37593-06-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 33 - 35 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C18H28O
Molecular Weight: 260

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 37593-06-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4-Decylphenyl)ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 37593-06-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 37593-06-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 37593-06-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  对癸基苯乙酮 在 selenium(IV) oxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 99.0h， 生成 Potassium; 2-[2-(4-decyl-phenyl)-1-hydroxy-2-oxo-ethyl]-3-oxo-hexanoate
  参考文献：
  名称：

  Liang, Jason, Journal of Heterocyclic Chemistry, 1984, vol. 21, p. 1297 - 1299

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(4-decylphenyl)-2-methyl-1,3-dithiane 在 methyltriphenylphosphonium tribromide 、 水 作用下， 生成 对癸基苯乙酮
  参考文献：
  名称：

  噻吩的1，3对二硫代苯乙缩醛脱硫缩醛

  摘要：

  三溴甲基三苯基phosph是一种有效的温和的脱硫缩酮化试剂，对2-苯基和2-乙烯基1，3-二噻烷相对于2-烷基1，3-二噻吩具有高选择性，而且所研究的底物没有任何二次溴化反应。用三溴化三甲基苯基铵也反应成功。

  DOI：

  10.1016/s0040-4039(00)84691-2

文献信息

• 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME
  申请人：Shibata Norio

  公开号：US20110319637A1

  公开（公告）日：2011-12-29

  A 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative as a monofluoromethyl group introduction agent that is effective as an intermediate in pharmaceutical and agrochemical synthesis, a production method thereof, and a production method of a monofluoromethyl group-containing compound using this 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative are provided. The 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative represented by the following general formula (1) (wherein R 1 , R 2 , R 3 , and R 4 each independently represent a hydrogen atom, a straight-chain or branched alkyl group having 1 to 4 carbon atoms, a straight-chain or branched alkyloxy group having 1 to 4 carbon atoms, a halogen atom, a nitro group, or a cyano group), the production method thereof, and various monofluoromethyl group-containing compounds are manufactured using this 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative as a monofluoromethylating agent.

  一种2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物作为单氟甲基基团引入剂，可作为制药和农药合成中间体，提供其生产方法，以及使用该2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物制备含单氟甲基基团的化合物的生产方法。所述2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物由下述通用式（1）表示（其中R1、R2、R3和R4各自独立地表示氢原子、具有1至4个碳原子的直链或支链烷基基团、具有1至4个碳原子的直链或支链烷氧基基团、卤素原子、硝基团或氰基团），提供其生产方法，并使用该2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物作为单氟甲基化剂制造各种含单氟甲基基团的化合物。
• 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids
  作者：Roger A. Parker、Takashi Kariya、J. Martin Grisar、Vladimir Petrow

  DOI：10.1021/jm00216a009

  日期：1977.6

  5-(Tetradecyloxy)-2-furancarboxylic acid (91, RMI 14514) was found to lower blood lipids and to inhibit fatty acid synthesis with minimal effects on liver weight and liver fat content. This fatty acid-like compound represents a new class of hypolipidemic agent; it is effective in rats and monkeys. The compound resulted from discovery of hypolipidemic activity in certain beta-keto esters, postulation

  发现5-（四氢癸氧基）-2-呋喃羧酸（91，RMI 14514）可以降低血脂并抑制脂肪酸合成，对肝脏重量和肝脏脂肪含量的影响最小。这种类似脂肪酸的化合物代表了一类新的降血脂药。对大鼠和猴子有效。该化合物的产生是由于发现了某些β-酮酸酯的降血脂活性，假定和确认了相应的苯甲酸作为活性代谢物以及系统地研究了结构-活性关系。
• Identification of selective inhibitors of sphingosine kinases 1 and 2 through a structure–activity relationship study of 4-epi-jaspine B
  作者：Hiroaki Ohno、Maho Honda、Naoka Hamada、Jun Miyagaki、Akira Iwata、Kazuhiro Otsuki、Toru Maruyama、Shinya Nakamura、Isao Nakanishi、Shinsuke Inuki、Nobutaka Fujii、Shinya Oishi

  DOI：10.1016/j.bmc.2017.03.059

  日期：2017.6

  We recently reported that 4-epi-jaspine B exhibits potent inhibitory activity towards sphingosine kinases (SphKs). In this study, we investigated the effects of modifying the 2-alkyl group, as well as the functional groups on the THF ring of 4-epi-jaspine B using a diversity-oriented synthesis approach based on a late-stage cross metathesis reaction. The introduction of a p-phenylene tether to the

  最近，我们报道了4-epi-jaspine B对鞘氨醇激酶（SphKs）表现出强大的抑制活性。在这项研究中，我们使用基于后期交叉复分解反应的面向多样性的合成方法，研究了修饰2-表山s B的2-烷基基团以及THF环上官能团的作用。在大多数情况下，将对亚苯基系链引入烷基是有利的，而用氧原子取代碳原子会导致抑制活性的降低。此外，在末端引入大分子烷基导致该系列对SphKs的抑制活性与4-eps-jaspine B相比略有增加（化合物13对SphK1和SphK2的Q值分别为0.2和0.4，分别）。根据这项研究，我们确定了两种同工型选择性抑制剂，包括间亚苯基衍生物4 [IC50（SphK1）≥30μM；IC50（SphK2）=2.2μM]和甲基醚衍生物22 [IC50（SphK1）=4.0μM; IC50（SphK2）≥30μM]。
• Discovery of In Vivo Active Sphingosine-1-phosphate Transporter (Spns2) Inhibitors
  作者：Russell Fritzemeier、Daniel Foster、Ashley Peralta、Michael Payette、Yugesh Kharel、Tao Huang、Kevin R. Lynch、Webster L. Santos

  DOI：10.1021/acs.jmedchem.1c02171

  日期：2022.6.9

  export is facilitated by Mfsd2b and spinster homologue 2 (Spns2). While mouse genetic studies suggest that Spns2 functions to maintain lymph S1P, Spns2 inhibitors are necessary to understand its biology and to learn whether Spns2 is a viable drug target. Herein, we report a structure–activity relationship study that identified the first Spns2 inhibitor 16d (SLF1081851). In vitro studies in HeLa cells demonstrated

  1-磷酸鞘氨醇 (S1P) 是一种多效性信号分子，可与 5 个 G 蛋白偶联受体 (S1P1-5) 相互作用来调节细胞信号传导通路。 Mfsd2b 和老处女同源物 2 (Spns2) 促进了 S1P 输出。虽然小鼠遗传学研究表明 Spns2 的功能是维持淋巴 S1P，但必须使用 Spns2 抑制剂才能了解其生物学特性并了解 Spns2 是否是可行的药物靶点。在此，我们报告了一项结构-活性关系研究，该研究鉴定了第一个 Spns2 抑制剂16d (SLF1081851)。 HeLa 细胞的体外研究表明， 16d抑制 S1P 释放，IC 50为 1.93 μM。给小鼠和大鼠施用16 天后，循环淋巴细胞计数和血浆 S1P 浓度显着下降，重现了在 Spns2 缺陷的小鼠中观察到的表型。因此， 16d具有开发和用作探针来研究 Spns2 生物学并确定 Spns2 作为药物靶点的潜力的潜力。
• Imidazole-based sphingosine-1-phosphate transporter Spns2 inhibitors
  作者：Christopher W. Shrader、Daniel Foster、Yugesh Kharel、Tao Huang、Kevin R. Lynch、Webster L. Santos

  DOI：10.1016/j.bmcl.2023.129516

  日期：2023.11

  Sphingosine-1-phosphate (S1P) is a chemotactic lipid that influences immune cell positioning. S1P concentration gradients are necessary for proper egress of lymphocytes from the thymus and secondary lymphoid tissues. This trafficking is interdicted by S1P receptor modulators, and it is expected that S1P transporter (Spns2) inhibitors, by reshaping S1P concentration gradients, will do the same. We previously

  1-磷酸鞘氨醇 （S1P） 是一种影响免疫细胞定位的趋化脂质。S1P 浓度梯度对于淋巴细胞从胸腺和次级淋巴组织正确流出是必要的。这种运输被 S1P 受体调节剂阻止，预计 S1P 转运蛋白 （Spns2） 抑制剂通过重塑 S1P 浓度梯度也会起到同样的作用。我们之前报道了 SLF1081851 作为原型 Spns2 抑制剂，它为研究噁二唑核心和末端胺的重要性提供了一个支架。在本报告中，我们通过将咪唑作为 SLF1081851 中正电荷的连接物和替代物来披露一项结构-活性关系研究。HeLa 细胞中 Spns2 依赖性 S1P 转运的体外抑制将 7b 确定为抑制剂，IC50 为 1.4 ± 0.3 μM。本文报道的 SAR 研究表明，咪唑铵可以替代 SLF1081851 中的末端胺，并且 Spns2 抑制高度依赖于脂质烷基尾部长度。